eligibility_summary
RRMM refractory to a PI, IMiD, and anti-CD38, measurable disease, SpO2 ≥92%, ECOG 0–2, compliant and using contraception. Exclude: recent anti-cancer/investigational therapy, allo-HSCT <6 mo, GVHD/immunosuppression, other malignancy (treated in last 3 yrs or not in CR), grade ≥3 paresis/ocular disorder, neuropathy ≥3 or 2 with pain, cytopenias, abnormal INR/aPTT, renal/hepatic dysfunction, NYHA >2, LVEF <40%, prolonged QTc, active infection (COVID, HIV, HBV/HCV), pregnant/breastfeeding, other high risk.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: STI-6129, an anti-CD38 antibody–drug conjugate (biologic ADC) comprising a human anti-CD38 monoclonal antibody covalently linked to a duostatin tubulin inhibitor. Mechanism: binds CD38 on multiple myeloma plasma cells, is internalized, and releases the duostatin payload to inhibit tubulin/microtubule polymerization, disrupting mitosis and inducing apoptosis, CD38 targeting may also engage immune-mediated effects. Targets: CD38-positive malignant plasma cells, microtubule/mitotic spindle machinery. Trial: Phase 1b/2a, open-label 3+3 dose escalation/expansion, IV every 4 weeks (0.67–3.68 mg/kg) in relapsed/refractory multiple myeloma.